Medikamentöse BPS-Therapie

Abstract

5alpha-Reductase inhibitors and alpha(1)-receptor blockers are established options for symptomatic treatment of benign prostatic hyperplasia (BPH). Achieving maximum efficacy is contingent on correct dosage and requires careful patient selection in view of the substance class employed. All applicable preparations exert only a low-grade effect on prostatic obstruction. This condition should be excluded by appropriate urological examination before treatment is initiated. If the patient's distress is minor, refraining from drug therapy can be considered. Symptomatic patients with small prostate volume are suited for monotherapy with alpha(1)-receptor blockers and symptomatic patients with large prostate volume profit from combination therapy. When 5alpha-reductase inhibitors are used, BPH patients should be made aware of the findings from the Prostate Cancer Prevention Trial.

Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia

“…A number of medical strategies have been attempted to treat BPH, but only two of them have achieved widespread acceptance, namely: inhibition of sympathetic tone in the prostate and bladder neck and suppression of androgen stimulation of prostatic growth. The symptomatic improvement produced by these drugs makes it possible to delay or eliminate surgery [3,4]. adrenergic receptor belongs to the superfamily of G-protein coupled receptors which transduce signals across the cell membrane, and are classified into three principal families: α 1 , α 2 and β.…”